Off Target.

• Autores: Gary Stix
• Localización: Scientific American, ISSN 0036-8733, Vol. 292, Nº. 3, 2005, págs. 30-30
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • This article reports on set backs to AstraZeneca's cancer drug. The drug industry has heralded targeted cancer therapies, which attack a specific protein identified through molecular analysis, as the next wave in treatment. This strategy received a setback last December, when the European drugmaker AstraZeneca reported that its targeted therapy, Iressa (gefitinib), shrank tumors but was no more effective than a placebo at extending the lives of patients with lung cancer. In light of this study, which included 1,700 people, AstraZeneca withdrew its application for approval in Europe.